Cue Biopharma (CUE) vs Emmis Acquisition (EMIS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cue Biopharma is the larger company by market cap ($163.5 million vs $162.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | EMIS |
|---|---|---|
| Share price | $22.51 | $10.27 |
| Market cap | $163.52M | $162.02M |
| 1-day change | -2.72% | 0.00% |
| YTD return | +146.01% | +3.22% |
| 1-year return | -0.22% | — |
| 5-year return | -94.04% | — |
| EPS (TTM) | $-28.75 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $10.27 |
| 52-week low | $4.98 | $9.90 |
| Distance from 52-week high | -50.53% | 0.00% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +290.94% | — |
| Average volume | 269.82K | 13.89K |
| Shares outstanding | 7.26M | 11.94M |
| Employees | 29 | — |
| Sector | Healthcare | Financial Services |
| Industry | Biotechnology | Shell Companies |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Cue Biopharma in Healthcare and Emmis Acquisition in Financial Services.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Healthcare · Biotechnology · 29 employees
About Emmis Acquisition
EMIS stock →Emmis Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Financial Services · Shell Companies
CUE vs EMIS FAQ
Which is bigger, Cue Biopharma or Emmis Acquisition?
Cue Biopharma (CUE) is larger, with a market capitalization of $163.52M compared with $162.02M for Emmis Acquisition (EMIS).
Are Cue Biopharma and Emmis Acquisition in the same industry?
No. Cue Biopharma is in the Healthcare sector, while Emmis Acquisition is in Financial Services.